PODCAST · health
Novel Therapies for Bleeding Disorders
by Canadian Hemophilia Society
Innovation is accelerating—not only in communications, computer technology, and artificial intelligence, but also in medical science. For people living with inherited bleeding disorders, this acceleration is transforming what is possible.Over the past decade, treatment advances have reshaped care. Extended half-life factor VIII and IX concentrates have reduced infusion frequency. Factor VIII mimetics such as emicizumab have introduced entirely new mechanisms of action. The first gene therapies for hemophilia A and B are now a reality. Rebalancing agents have entered the therapeutic landscape. And this is only the beginning.A growing pipeline of innovative therapies—subcutaneous treatments, non-factor therapies, gene editing approaches, rebalancing strategies, and more—are in various stages of development. These advances extend beyond hemophilia to include von Willebrand disease and rare bleeding disorders such as Glanzmann Thrombasthenia and others that historically re
-
4
Maladie de Von Willebrand et Thrombasthénie de Glanzmann
Dans ce balado, DR ROY KHALIFÉ nous parlera des traitements qui pourraient être accessibles à l'avenir pour traiter la maladie de von Willebrand et la thrombasthénie de Glanzmann, des maladies qui n'ont pas bénéficié jusqu'à présent des progrès de la recherche clinique autant que l’hémophilie A et B.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
3
VWD and Glanzmann Thrombasthenia
In this episode, DR. ROY KHALIFÉ will explore therapies that may become available in the future to treat von Willebrand disease and Glanzmann Thrombasthenia, conditions that have not benefitted from clinical research advances to the same degree as hemophilia A and B until now.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
2
Prochains Traitements Sur le Marché Canadien
Dans ce balado, DR ROY KHALIFÉ, professeur adjoint à l'Université d'Ottawa et codirecteur du Programme régional d'Ottawa pour les troubles de la coagulation chez les adultes à l'Hôpital d'Ottawa, nous parlera de traitements pour différents troubles de la coagulation qui pourraient être accessibles au Canada au cours des deux ou trois prochaines années.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
-
1
Next Therapies on the Canadian Market
In this episode, DR. ROY KHALIFÉ, Assistant Professor at the University of Ottawa and co-director of the Ottawa Regional Adult Bleeding Disorders Program at the Ottawa Hospital, will explore therapies for various bleeding disorders that have the potential to be available in Canada in the next couple of years.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
Innovation is accelerating—not only in communications, computer technology, and artificial intelligence, but also in medical science. For people living with inherited bleeding disorders, this acceleration is transforming what is possible.Over the past decade, treatment advances have reshaped care. Extended half-life factor VIII and IX concentrates have reduced infusion frequency. Factor VIII mimetics such as emicizumab have introduced entirely new mechanisms of action. The first gene therapies for hemophilia A and B are now a reality. Rebalancing agents have entered the therapeutic landscape. And this is only the beginning.A growing pipeline of innovative therapies—subcutaneous treatments, non-factor therapies, gene editing approaches, rebalancing strategies, and more—are in various stages of development. These advances extend beyond hemophilia to include von Willebrand disease and rare bleeding disorders such as Glanzmann Thrombasthenia and others that historically re
HOSTED BY
Canadian Hemophilia Society
Loading similar podcasts...
Frequently Asked Questions
How many episodes does Novel Therapies for Bleeding Disorders have?
Novel Therapies for Bleeding Disorders currently has 4 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.
What is Novel Therapies for Bleeding Disorders about?
Innovation is accelerating—not only in communications, computer technology, and artificial intelligence, but also in medical science. For people living with inherited bleeding disorders, this acceleration is transforming what is possible.Over the past decade, treatment advances have reshaped care....
How often does Novel Therapies for Bleeding Disorders release new episodes?
Novel Therapies for Bleeding Disorders has 4 episodes. Check the episode list to see recent publication dates and frequency.
Where can I listen to Novel Therapies for Bleeding Disorders?
You can listen to Novel Therapies for Bleeding Disorders on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.
Who hosts Novel Therapies for Bleeding Disorders?
Novel Therapies for Bleeding Disorders is created and hosted by Canadian Hemophilia Society.
URL copied to clipboard!